Program
SOS1 Inhibitor MRTX0902
Its studies are mostly in Gastrointestinal Stromal Tumors · Hematologic Neoplasms, led by Kumquat Biosciences.
Furthest: phase 2, since Jan 23, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kumquat Biosciences | 33 open or running | phase 2since Jan 23, 2026 | Jul 1, 2024 | Dec 31, 2026phase 1 · NCT06507306 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2024First study: phase 1 study in Solid Tumor, AdultFirst studyNCT06507306 · 92 enrolled · United States, France, Italy and more
- Oct 2, 2024Phase 1 study in Hematologic NeoplasmsNCT06645886 · 13 enrolled · United States, France, Germany and more
- Jan 23, 2026Phase 2 study in Gastrointestinal Stromal TumorsPhase 2 reachedNCT07406633 · 46 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Solid Tumor, AdultNCT06507306
- Mar 2027Primary completion: phase 1 study in Hematologic NeoplasmsNCT06645886
- Oct 2027Primary completion: phase 2 study in Gastrointestinal Stromal TumorsNCT07406633
TargetBeta
“An orally available inhibitor of the guanine nucleotide exchange factor (GEF) Son of sevenless homolog 1 (SOS1), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07406633Gastrointestinal Stromal Tumors · United States | 2 | Recruiting | Oct 2027 | 46 |
| NCT06645886Hematologic Neoplasms · United States, France, Germany and more | 1 | Active, not recruiting | Mar 2027 | 13 |
| NCT06507306Solid Tumor, Adult · United States, France, Italy and more | 1 | Active, not recruiting | Dec 31, 2026 | 92 |
How it is read
Names in the registry
- “KQB198”, 3 entries
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.